Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Cu-AKY-1189

Phase 1Small molecule

AAktis Oncology, Inc.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Urothelial Carcinoma BladderRecruiting

Urothelial Carcinoma BladderPhase 1

Recruiting

Timeline

Expected Milestones

Q2 2032

Phase 1Recruiting

Urothelial Carcinoma Bladder

NCT07020117

Clinical

Trials by Indication[1]

Urothelial Carcinoma Bladder1 trial

NECTINIUM-2: A Phase 1b, 2 Part, Multicenter, Single Arm, Open Label Study to Evaluate the Safety and Efficacy of a Nectin-4 Radiopharmaceutical ([225Ac]Ac-AKY-1189) in Patients With Previously Treated Locally Advanced or Metastatic Solid Tumors

Recruiting·AAktis Oncology, Inc.·Phase 1·NCT07020117·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cu-AKY-1189. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cu-AKY-1189 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cu-AKY-1189. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aktis Oncology, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AAktis Oncology, Inc.

Related News